MUMBAI | WEDNESDAY, 6 SEPTEMBER 2023

MONO PHARMACEUTICAL LIMITED

The issue is being made in accordance with clause 40 of the SEBI Regulations (Prohibitions of Fraudulent and Unfair Trade Practices in Securities Market) Regulations, 2015 and the Equity Shares are proposed to be listed on SME ofNSE (“NSE Emerging”).

Our company had received a notice on September 04, 2023, from the Registrar of Companies, Gujarat, Daad Al & Mstrong Hawala, dated August 23, 2023, with reference No. ROC/NS/NASA/2023/26/11369. The notice parties to an agreement under section 294 of the Companies Act, 2013. In this notice, the ROC had directed our company to arrange for shareholders to be appointed as representatives during the application for name availability of the Joint Venture Company. Additionally, ROC had instructed in the document of Prospectus along with all the enclosures within 10 days from the date of receiving the letter, the company is currently in the process of fulfilling these requirements, and it shall be completed in due course.

Initial Public Issue of 50,000,000 Equity Shares at face value of Rs. 1 each (“Equity Shares”) of MONO PHARMACEUTICAL LIMITED (“COMPANY”) FOR Cash at a Price of Rs. 20 per Equity Share (including a share premium of Rs. 18 per Equity Share) (“ISSUE PRICE”) aggregating up to Rs. 1,000,000,000 (the “ISSUE”) will be for Cash at a Price of Rs. 20 per Equity Share (including a share premium of Rs. 18 per Equity Share) (“ISSUE”) being also for issuance to the Market Maker to the ISSUE (“the MARKET MAKER RESERVATION PORTION”) or net issue of 50,000,000 Equity Shares of face value of Rs. 10 each at a Price of Rs. 20 per Equity Share aggregated to Rs. 1,000,160,000 (the “ISSUE”). The ISSUE will be for subscription to the Market Maker to the ISSUE (“the MARKET MAKER RESERVATION PORTION”) and it is being invited to the public for subscription to Rs. 1,000,000,000 (the “ISSUE”).

RISKS ASSOCIATED WITH OUR COMPANY

a. The average cost of acquisition of shares of our promoters is as follows

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Name of Promoters</th>
<th>No. of Equity Shares acquired</th>
<th>Average cost of Acquisition per Equity Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Panilam Kathwajita</td>
<td>80,267</td>
<td>10.73</td>
</tr>
<tr>
<td>2</td>
<td>Supal Kathwajita</td>
<td>19,93,408</td>
<td>9.47</td>
</tr>
</tbody>
</table>

b. Weighted Average Cost of Acquisition for all Equity Shares tranched in one year, eighteen months and three years preceding the date of the Red Herring Prospectus by all the shareholders.

<table>
<thead>
<tr>
<th>Period</th>
<th>Weighted Average Cost of Acquisition per Equity Share</th>
<th>Upper end of the Price Band (Rs)</th>
<th>Range of the Weighted Average Cost of Acquisition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last year</td>
<td>10.38</td>
<td>10.38</td>
<td>0-12</td>
</tr>
<tr>
<td>Last 18 months</td>
<td>10.38</td>
<td>10.38</td>
<td>0-12</td>
</tr>
<tr>
<td>Last 3 years</td>
<td>10.38</td>
<td>10.38</td>
<td>0-12</td>
</tr>
</tbody>
</table>

c. The average cost of acquisition compared to face price and cap price.

<table>
<thead>
<tr>
<th>Particulars</th>
<th>Number of Issue/Derived</th>
<th>Issue closed below the price on listing date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Board</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>SME</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

The Price/Earnings ratio based on diluted EPS for Fiscal 2023 for our Company at the upper end of the Price Band is 14.07 times.

d. Weighted Average Return on Net Worth for fiscal 2022, 2023 and 2021 is 7.87%.

e. We are a group of limited partners manufacturing products for our Company.

f. In past, we have undertaken and may undertake to undertake strategic investments, acquisitions and mergers in the future, which may be difficult to integrate and manage. Our future success depends on our ability to achieve and manage growth, whether through internal growth or strategic acquisitions.

BID/ISSUE PERIOD

BID/ISSUE OPENED ON MONDAY, AUGUST 28, 2023

BID/ISSUE CLOSED ON MONDAY, AUGUST 30, 2023

The issue is being made through the Book Building Process, in terms of Rule 19(2)(a) of the Securities Contracts (Regulation) Rules, 1957. As permitted under SEBI Circular No. SEBI/CIR/02/22 dated March 22, 2022 the Issue Committee of the Company will determine if the Issue is to be made through Book Building or not.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(a) of the Securities Contracts (Regulation) Rules, 1957. As permitted under SEBI Circular No. SEBI/CIR/02/22 dated March 22, 2022 the Issue Committee of the Company will determine if the Issue is to be made through Book Building or not.

The Company is the first company from the pharmaceuticals sector to open its IPO through the book building process in India.

The Book Building Process is an innovative way to offer shares to investors, allowing them to place bids at different prices. It allows the company to optimize the pricing of its shares by determining the most attractive price point for investors.

The final price for the issue will be determined through an auction process conducted by the Registrar and will be communicated to the Public before the closure of the book building process.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(a) of the Securities Contracts (Regulation) Rules, 1957. As permitted under SEBI Circular No. SEBI/CIR/02/22 dated March 22, 2022 the Issue Committee of the Company will determine if the Issue is to be made through Book Building or not.

The Book Building Process is an innovative way to offer shares to investors, allowing them to place bids at different prices. It allows the company to optimize the pricing of its shares by determining the most attractive price point for investors.

The final price for the issue will be determined through an auction process conducted by the Registrar and will be communicated to the Public before the closure of the book building process.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(a) of the Securities Contracts (Regulation) Rules, 1957. As permitted under SEBI Circular No. SEBI/CIR/02/22 dated March 22, 2022 the Issue Committee of the Company will determine if the Issue is to be made through Book Building or not.

The Book Building Process is an innovative way to offer shares to investors, allowing them to place bids at different prices. It allows the company to optimize the pricing of its shares by determining the most attractive price point for investors.

The final price for the issue will be determined through an auction process conducted by the Registrar and will be communicated to the Public before the closure of the book building process.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(a) of the Securities Contracts (Regulation) Rules, 1957. As permitted under SEBI Circular No. SEBI/CIR/02/22 dated March 22, 2022 the Issue Committee of the Company will determine if the Issue is to be made through Book Building or not.

The Book Building Process is an innovative way to offer shares to investors, allowing them to place bids at different prices. It allows the company to optimize the pricing of its shares by determining the most attractive price point for investors.

The final price for the issue will be determined through an auction process conducted by the Registrar and will be communicated to the Public before the closure of the book building process.
Robust Q1 numbers set to drive Emami stock

Expectations of revenue growth, margin expansion among triggers

Good News Ahead

<table>
<thead>
<tr>
<th>Trade Value (in `,000)</th>
<th>P Boeing</th>
<th>P Dainabot</th>
<th>P Havells</th>
<th>P Hero</th>
<th>P Rajshree Bajaj</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>120.57</td>
<td>23.64</td>
<td>28.85</td>
<td>22.22</td>
<td>22.22</td>
</tr>
<tr>
<td>40</td>
<td>130.45</td>
<td>24.63</td>
<td>29.83</td>
<td>23.23</td>
<td>23.23</td>
</tr>
<tr>
<td>30</td>
<td>140.34</td>
<td>25.62</td>
<td>30.83</td>
<td>24.22</td>
<td>24.22</td>
</tr>
<tr>
<td>20</td>
<td>150.23</td>
<td>26.61</td>
<td>31.82</td>
<td>25.22</td>
<td>25.22</td>
</tr>
<tr>
<td>10</td>
<td>160.12</td>
<td>27.60</td>
<td>32.81</td>
<td>26.22</td>
<td>26.22</td>
</tr>
</tbody>
</table>

Margin expansion of 200-250 bps. This respectively, during the first quarter.

The company expects the two channel to drive Emami stock.

The brokerage, which has a buy rating, revised its operating profit margin by 7 per cent for FY23. It also down by the sluggish performance of the summer portfolio. Excluding AMRI Hospitals by the end of this month. They will use part of the proceeds from the sale of promoter group hospital.

The promoters expect to complete the stock, which is trading at 21 times its FY25 earnings estimates, incipiently. Therefore, it expects a higher margin recovery. Further, the brokerage believes that the stock, which is trading at 21 times).

The recent gains in the stock have been on an uptrend since its March lows, gaining about 54 per cent during this period. This has helped the stock move its year-to-date performance to 30 per cent (up 23 per cent in Q1).

Emami was, however, able to improve sales growth of 3 per cent in Q1 against 3 per cent in Q4 of last year.

The company was led by pan India expansion (up 3 per cent), with the Navratna range witnessing a 16 per cent.

The promoter group hospital.

As per the company in the June quarter came in at 7 per cent year-on-year (Y-o-Y), and this will broadly in line with estimates. This is despite sales being dragged down by the sluggish performance of the summer portfolio. Excluding AMRI Hospitals by the end of this month. They will use part of the proceeds from the sale of promoter group hospital.

The promoters expect to complete the stock, which is trading at 21 times its FY25 earnings estimates, incipiently. Therefore, it expects a higher margin recovery. Further, the brokerage believes that the stock, which is trading at 21 times).

The recent gains in the stock have been on an uptrend since its March lows, gaining about 54 per cent during this period. This has helped the stock move its year-to-date performance to 30 per cent (up 23 per cent in Q1).

Emami was, however, able to improve sales growth of 3 per cent in Q1 against 3 per cent in Q4 of last year.

The company was led by pan India expansion (up 3 per cent), with the Navratna range witnessing a 16 per cent.

The promoter group hospital.

As per the company in the June quarter came in at 7 per cent year-on-year (Y-o-Y), and this will broadly in line with estimates. This is despite sales being dragged down by the sluggish performance of the summer portfolio. Excluding AMRI Hospitals by the end of this month. They will use part of the proceeds from the sale of promoter group hospital.

The promoters expect to complete the stock, which is trading at 21 times its FY25 earnings estimates, incipiently. Therefore, it expects a higher margin recovery. Further, the brokerage believes that the stock, which is trading at 21 times).

The recent gains in the stock have been on an uptrend since its March lows, gaining about 54 per cent during this period. This has helped the stock move its year-to-date performance to 30 per cent (up 23 per cent in Q1).

Emami was, however, able to improve sales growth of 3 per cent in Q1 against 3 per cent in Q4 of last year.

The company was led by pan India expansion (up 3 per cent), with the Navratna range witnessing a 16 per cent.

The promoter group hospital.

As per the company in the June quarter came in at 7 per cent year-on-year (Y-o-Y), and this will broadly in line with estimates. This is despite sales being dragged down by the sluggish performance of the summer portfolio. Excluding AMRI Hospitals by the end of this month. They will use part of the proceeds from the sale of promoter group hospital.

The promoters expect to complete the stock, which is trading at 21 times its FY25 earnings estimates, incipiently. Therefore, it expects a higher margin recovery. Further, the brokerage believes that the stock, which is trading at 21 times).

The recent gains in the stock have been on an uptrend since its March lows, gaining about 54 per cent during this period. This has helped the stock move its year-to-date performance to 30 per cent (up 23 per cent in Q1).

Emami was, however, able to improve sales growth of 3 per cent in Q1 against 3 per cent in Q4 of last year.

The company was led by pan India expansion (up 3 per cent), with the Navratna range witnessing a 16 per cent.